Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 8:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 21,755 matching trials from the live ClinicalTrials.gov search.
Conditions
Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura
Interventions
ARC 1779 Placebo, ARC1779 Injection
Drug
Lead sponsor
Archemix Corp.
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
7
States / cities
Chicago, Illinois • Indianapolis, Indiana • St Louis, Missouri + 4 more
Conditions
Adolescent Health Services, Immunization
Interventions
Assessment , Feedback, Incentives, and eXchange Program
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Conditions
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
Saruparib, Placebo, Enzalutamide, Darolutamide, Abiraterone
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
42
States / cities
Hot Springs, Arkansas • Springdale, Arkansas • Beverly Hills, California + 36 more
Completed No phase listed Observational Accepts healthy volunteers

Limb Cooling in Essential Tremor

NCT02067702
Conditions
Essential Tremor
Interventions
Limb Cooling Assessment of ET
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 95 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Aripiprazole, Haloperidol, Olanzapine, Oral Paliperidone ER, Perphenazine, Quetiapine, Oral Risperidone, Paliperidone Palmitate Injection (PP1M), Paliperidone Palmitate Injection (PP3M)
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 35 Years
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
34
States / cities
Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 31 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Bi-Lateral Tubal Occlusion Trial for Female Permanent Contraception

NCT03067272
Conditions
Contraception
Interventions
FemBloc® Permanent Contraceptive System
Device
Lead sponsor
Femasys Inc.
Industry
Eligibility
21 Years to 45 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
5
States / cities
Stamford, Connecticut • Miami, Florida • New York, New York + 2 more
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo, Ianalumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
25
States / cities
Anniston, Alabama • Burbank, California • La Palma, California + 22 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safety and Effectiveness of Juvederm(R) Ultra XC Injectable Gel for Lip Augmentation

NCT01197495
Conditions
Lip Augmentation
Interventions
hyaluronic acid gel
Device
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Suspended No phase listed Observational Accepts healthy volunteers

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

NCT04306939
Conditions
Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis, Acute Pancreatitis, Rheumatoid Arthritis, Diabetes Mellitus, Dyslipidemias, Multiple Sclerosis, Irritable Bowel Syndrome, Chronic Pain, Chronic Disease, Chronic Kidney Diseases, Crohn Disease, Celiac Disease, Biliary Cirrhosis, Bile Acid Synthesis Defect, Gastritis, Cholecystitis, Cholelithiases, IPMN, Cyst Pancreas, Cystic Fibrosis, Pancreatic Exocrine Insufficiency, Diarrhea Chronic, Constipation - Functional, Constipation Chronic Idiopathic
Interventions
venipuncture, Questionnaires, Additional Sample Collections
Other · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
120,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Lice Infestations
Interventions
MALG, Ovide (malathion) lotion 0.05%, Permethrin 1%
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
2 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Scottsdale, Arizona • Miami, Florida • St. Petersburg, Florida + 3 more
Conditions
Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease, Myocardial Infarct, Atherosclerotic Coronary Vascular Disease
Interventions
Orticumab, Placebo
Drug
Lead sponsor
Abcentra
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Torrance, California • Boca Raton, Florida + 4 more
Conditions
Primary Biliary Cholangitis
Interventions
Saroglitazar Magnesium 1 mg, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lakewood Rch, Florida
Conditions
Asthma
Interventions
Fluticasone propionate, Fluticasone furoate, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
55
States / cities
Birmingham, Alabama • Montgomery, Alabama • Green Valley, Arizona + 45 more
Conditions
Lung Carcinoma
Interventions
Varenicline, Placebo, Tobacco Cessation Counseling
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
374
States / cities
Fairbanks, Alaska • Kingman, Arizona • Jonesboro, Arkansas + 236 more
Conditions
PostTraumatic Stress Disorder
Interventions
Ropivacaine, Sham treatment
Drug
Lead sponsor
RTI International
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Honolulu, Hawaii • Fort Bragg, North Carolina
Completed Phase 1 Interventional Accepts healthy volunteers

Neulasta in Type 1 Diabetes

NCT00662519
Conditions
Type 1 Diabetes
Interventions
Neulasta (Pegylated), Placebo, Mixed Meal Tolerance Test (MMTT), Blood test, DNA Test
Drug · Dietary Supplement · Other
Lead sponsor
University of Florida
Other
Eligibility
12 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Acute Ischemic Stroke
Interventions
Acetylcysteine, Dextrose in Water
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Torrance, California
Conditions
Musculoskeletal Pain, Chronic Shoulder Pain, Shoulder Tendinopathy
Interventions
Digital rehabilitation, Conventional rehabilitation
Device
Lead sponsor
Sword Health, SA
Industry
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Francisco, California
Conditions
Gout, Hyperuricemia
Interventions
SAP-001
Drug
Lead sponsor
Shanton Pharma Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Anaheim, California • DeLand, Florida • High Point, North Carolina
Conditions
Healthy
Interventions
GSK2336805 30 mg, GSK2336805 60 mg, GSK2336805 120 mg, TMC435 150 mg (Treatment A), GSK2336805 60 mg (Treatment B and part of Treatment C and D), TMC435 100 mg (part of Treatment C), TMC435 150 mg (part of treatment D)
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
20 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cypress, California
Conditions
Anxiety
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Rett Syndrome
Interventions
fenfluramine hydrochloride, Placebo
Drug · Other
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
5 Years to 35 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
8
States / cities
Little Rock, Arkansas • Miami, Florida • Orlando, Florida + 5 more
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban

NCT00511134
Conditions
Insomnia, Nicotine Dependence
Interventions
Eszopiclone, Bupropion
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Relapsing Multiple Sclerosis
Interventions
Atacicept, Placebo matched to atacicept
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Phoenix, Arizona • Atlanta, Georgia • Northbrook, Illinois + 5 more